Ortiz Andrea C, Yañez Osvaldo, Salas-Huenuleo Edison, Morales Javier O
Department of Pharmaceutical Science and Technology, School of Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago 8380494, Chile.
Advanced Center for Chronic Diseases (ACCDiS), Santiago 8380492, Chile.
Pharmaceutics. 2021 Apr 10;13(4):531. doi: 10.3390/pharmaceutics13040531.
Lipid nanocarriers have a great potential for improving the physicochemical characteristics and behavior of poorly water-soluble drugs, such as aqueous dispersibility and oral bioavailability. This investigation presents a novel nanostructured lipid carrier (NLC) based on a mixture of solid lipid glycerides, fatty acid esters of PEG 1500 (Gelucire 44/14), and an oil mix composed of capric and caprylic triglycerides (Miglyol 812). These NLCs were developed by a simple low-energy method based on melt emulsification to yield highly encapsulating and narrowly distributed nanoparticles (~100 nm, PdI = 0.1, and zeta potential = ~-10 mV). Rhodamine 123 was selected as a poorly water-soluble drug model and owing to its spectroscopic properties. The novel NLCs were characterized by dynamic light scattering (DLS), zeta potential, nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), and colloidal stability. The drug release was determined through a dialysis bag and vertical Franzs' cells to provide insights about the methods' suitability, revealing similar performance regardless of their different fluid dynamics. Rhodamine 123 followed a characteristic biphasic release profile owing to the swelling of the hydrophilic polymer coating and diffusion process from the lipid core as revealed by the Korsmeyers-Peppas kinetic modeling. Moreover, to elucidate the formation and incorporation of Rhodamine 123 into the NLC core, several molecular dynamics simulations were conducted. The temperature was shown to be an important condition to improve the formation of the nanoparticles. In addition, the liquid lipid incorporation to the formulation forms nanoparticles with imperfect centers, in contrast to nanoparticles without it. Moreover, Miglyol 812 improves hydrophobic molecule solubility. These results suggest the potential of novel NLC as a drug delivery system for poorly water-soluble drugs.
脂质纳米载体在改善难溶性药物的物理化学特性和行为方面具有巨大潜力,例如水分散性和口服生物利用度。本研究提出了一种新型纳米结构脂质载体(NLC),它基于固体脂质甘油酯、聚乙二醇1500脂肪酸酯(Gelucire 44/14)以及由辛酸甘油三酯和癸酸甘油三酯组成的油相混合物(Miglyol 812)。这些NLC通过基于熔融乳化的简单低能方法制备,以产生具有高包封率和窄分布的纳米颗粒(100 nm,多分散指数=0.1,zeta电位= -10 mV)。由于罗丹明123的光谱特性,它被选为难溶性药物模型。通过动态光散射(DLS)、zeta电位、纳米颗粒跟踪分析(NTA)、透射电子显微镜(TEM)、差示扫描量热法(DSC)和胶体稳定性对新型NLC进行了表征。通过透析袋和垂直Franz扩散池测定药物释放,以了解这些方法的适用性,结果表明无论流体动力学如何不同,它们的性能相似。如Korsmeyers-Peppas动力学模型所示,由于亲水性聚合物包衣的溶胀和脂质核心的扩散过程,罗丹明123呈现出典型的双相释放曲线。此外,为了阐明罗丹明123在NLC核心中的形成和掺入情况,进行了几次分子动力学模拟。结果表明温度是改善纳米颗粒形成的重要条件。此外,与不含液态脂质的纳米颗粒相比,在制剂中加入液态脂质会形成中心不完美的纳米颗粒。此外,Miglyol 812提高了疏水分子的溶解度。这些结果表明新型NLC作为难溶性药物递送系统的潜力。